Syncell
Livermore
About Syncell
Syncell is a proteomics technology company enabling disease site-specific protein drug target discovery. Its pioneering Microscoop™ technology enables microscopy-guided nanoscale protein "scooping", making unbiased subcellular spatial proteomic discovery feasible for the first time. This technology can be applied to a broad range of biological problems to help identify novel disease biomarkers and reveal novel druggable targets.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $59.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2025)
- Website: syncell.com
- Phone: 925-495-4858
Industries & Categories
Life Science
Social Profiles
Canonical: https://fsome.com/organization/syncell-2830 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.